Traditional Chinese medicine formula for treating lung and kidney qi deficiency syndrome of chronic obstructive pulmonary disease and application thereof

Abstract

The invention relates to a traditional Chinese medicine formula for treating lung and kidney qi deficiency syndrome of chronic obstructive pulmonary disease (COPD). The problem of the medicine for treating the lung and kidney qi deficiency patient in the stable period of COPD is effectively solved. The traditional Chinese medicine formula comprises 6-20mg ginseng extract, 10-100mg icariin, 1-8mg paeonol, 0.5-6mg nobiletin, 5-20mg paeoniflorin, 3-12mg schisandrin b, 1-8mg peimine, 5-20mg hesperidin, 3-12mg astragalus polysaccharide and 1-8mg astragaloside. The traditional Chinese medicine formula provided by the invention can be effectively applied to the treatment for the lung and kidney qi deficiency syndrome of chronic obstructive pulmonary disease and the preparation of the preparationthereof. Repeated test proves that the traditional Chinese medicine formula is capable of improving COPD lung function, relieving lung tissue pathological injury and inflammatory cell infiltration andimproving inflammatory response and oxidative stress and can be used as long-term used medicine in the stable period for treating COPD. The traditional Chinese medicine formula has the advantages ofreasonable composition, scientific method, high innovation, accurate curative effect and obvious economic and social benefits.

Description

1. Technical field [0001] The invention relates to medicine, in particular to a traditional Chinese medicine composition (also known as Jinshui Yifei prescription, the same below) for treating chronic obstructive pulmonary disease with deficiency of lung and kidney qi. 2. Background technology [0002] Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation associated with airway and / or alveolar abnormalities caused by exposure to noxious particles or gases. COPD is a serious threat to public health, with high morbidity, disability, and mortality, and a heavy social and economic burden. According to statistics, in 2012, 3 million people worldwide died of COPD, accounting for 6% of the total number of deaths in that year. The quality of life of COPD patients is severely reduced. Their own physical and psychological pain and the impact on their relatives are no less than that of cancer, and even worse than cancer...

AI Technical Summary

Problems solved by technology

The clinical drugs for treating COPD include β2 receptor agonists, bronchodilators, glucocorticoids, aminophylline, etc., combined with smoking cessation, oxygen therapy, nutritional support, and respiratory muscle function exercise, but no certain therapeutic drugs or methods have been found yet. It can effectively inhibit the decline of lung function and delay the progress of the disease, and even some drugs have more side effects than curative effects, such as glucocorticoids aggravate microvascular damage, and the effective dose of aminophylline is very close to its toxic dose, etc.

Images